Immune checkpoint inhibitors (ICIs) have limited efficacy in metastatic colorectal cancer (mCRC) with proficient mismatch repair and microsatellite stability (pMMR/MSS), with liver metastases emerging as a dominant determinant of resistance. Whether this reflects a failure to activate antitumor immunity or a failure to direct it remains unclear. We investigated this in the phase II SERPENTINE trial of dual PD-L1 and CTLA-4 blockade by integrating paired pre-treatment and on-treatment single-cell transcriptomic and T-cell receptor (TCR) profiling (388,196 cells; 95,617 clonotypes) metastatic bi
Site-specific immune remodeling underlies resistance to dual immune checkpoint blockade in metastatic colorectal cancer
calendar_today
October 23, 2026
person
Baraibar, I., Morabito, S., Deuner-Cos, G., Caratu, G., Melero, J. L., Berasategi, M., Soto, M., Grzelak, M., Nieto, P., Maspero, D., Salva, F., Saoudi, N., Ros, J., Perez-Lopez, R., Gros, A., Villacampa, G., Roson, N., Carmona, J., Garcia, A., Lambert, A., Martinez-Martin, N., Casbas-Hernandez, P., Zeron-Medina, J., Tabernero, J., Rotem, A., Nieto, J. C., Elez, E., Heyn, H.
domain
medrxiv